Azusa Tanimoto

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells

Hirokazu Taniguchi, Tadaaki Yamada, Rong Wang et al. · Nature Communications · 2019 · 363 citations · Full text

Medicine, Oncology, Pharmacology +17

Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer

Rong Wang, Tadaaki Yamada, Kenji Kita et al. · Nature Communications · 2020 · 113 citations · Full text

Medicine, Oncology, Pharmacology +16

Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes

Simon Heeke, Carl M. Gay, Marcos R. Estecio et al. · Cancer Cell · 2024 · 112 citations · Full text

Medicine, Molecular Biology, Oncology +17

Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of <i>ALK</i> Mutation Status

Koji Fukuda, Shinji Takeuchi, Sachiko Arai et al. · Cancer Research · 2019 · 96 citations

Medicine, Cancer Biology, Oncology +16

Histone Deacetylase 3 Inhibition Overcomes <i>BIM</i> Deletion Polymorphism–Mediated Osimertinib Resistance in <i>EGFR-</i> Mutant Lung Cancer

Azusa Tanimoto, Shinji Takeuchi, Sachiko Arai et al. · Clinical Cancer Research · 2016 · 85 citations

Medicine, Oncology, Pharmacology +16